PO.CL01.13 · 临床研究
癌组织中神经内分泌参与的空间组学检测
Spatialomics detection of neuroendocrine involvement in cancer tissue
作者与单位 Authors & Affiliations
摘要 Abstract
中文摘要
在炎症、神经元损伤、癌症和神经退行性疾病中观察到的神经内分泌参与研究是一个新兴领域,为当前难治性疾病的干预和治疗提供了新机遇。已知癌细胞会侵入神经元周围的空间(神经周围侵袭),并从神经纤维及其神经递质、分泌的胺类和肽类中获得促生存和抗凋亡的益处。新神经组织的形成是预后不良癌症的一个特征。我们提出一种空间组学方法,将多重免疫组织化学(IHC)与 mRNA 原位杂交(ISH)检测相结合,以检查神经内分泌参与的微环境以及与这些组织和浸润性免疫细胞相关的生物标志物。我们在具有神经内分泌参与的 FFPE 组织中对蛋白质和 mRNA 的丰度及分布进行成像。ISH 检测采用单链支化 DNA 扩增方案(ss-bDNA)进行单分子检测,而 IHC 检测对中高丰度靶标采用直接抗体标记,对低丰度靶标采用酶促信号扩增。我们提出了具有显著改进的方案修改,最大限度地减少了 IHC 与 ISH 之间的不兼容性(否则会导致信号减弱或丢失)。这些修改保留了 IHC 和 ISH 信号,最大限度地减少了自发荧光,并缩短了多重工作流程所需的方案时间。我们展示了在相关组织中对神经生物标志物(如 S100B、CD56、胶质纤维酸性蛋白(GFAP)、嗜铬粒蛋白 A(CgA)和突触素)的多重 IHC 标记,这些标志物常在某些肿瘤的非内分泌结构和组织以及神经退行性疾病模型中过表达。神经 mRNA 表达的存在,结合免疫标志物(如 FoxP3 和 PD-1、PD-L1)以及增殖标志物(PCNA 和 Ki-67)在癌组织中的表达,揭示了肿瘤免疫微环境中的神经内分泌参与。仅供研究使用。不用于诊断程序。
查看英文原文 English abstract
The study of neuroendocrine involvement observed in inflammation, neuronal damage, cancer, and neurodegenerative disease is an emerging field offering new opportunities of intervention and treatment of currently intractable disease. Cancer cells are known to invade the space surrounding neurons (perineuronal invasion) and derive pro-survival and anti-apoptotic benefits from the nerve fibers and their neurotransmitters, secreted amines and peptides. Formation of new neural tissue is a characteristic of cancer with poor prognosis. We present a spatial-omics approach of multiplexing immunohistochemistry (IHC) with mRNA in situ hybridization (ISH) detection to examine the microenvironment of neuroendocrine involvement and the biomarkers relevant to these tissues and infiltrating immune cells. We image both protein and mRNA abundance and distribution in FFPE tissue with neuroendocrine involvement. ISH detection uses single stranded branched DNA amplification scheme (ss-bDNA) for single molecule detection, while IHC detection uses direct antibody labeling for moderate and high abundant targets and enzymatic signal amplification for low abundant targets. We present protocol modifications with significant improvements minimizing incompatibility between IHC and ISH otherwise resulting in diminished or loss of signal. These modifications retain IHC and ISH signal, minimize auto-fluorescence, and shorten protocol time required for multiplexed workflows. We show multiplex IHC labeling of neural biomarkers such as S100B, CD56, glial fibrillary acidic protein (GFAP), chromogranin A (CgA) and synaptophysin in relevant tissue which are often over-expressed in non-endocrine structures and tissues of some tumors, and in neurodegenerative disease models. The presence of neural mRNA expression, combined with immune markers such as FoxP3 and PD-1, PD-L1 and proliferation markers of PCNA and Ki-67 in cancer tissue, reveal the neuroendocrine involvement in the tumor immune microenvironment. For Research Use Only. Not for use in diagnostic procedures.
利益披露 Disclosure
S. T. Clarke,
Thermo Fisher Scientific Employment.
C. Vonnegut,
Thermo Fisher Scientific Employment.
L. Montoya,
Thermo Fisher Scientific Employment.
M. Voeun,
Thermo Fisher Scientific Employment.
W. Zhou,
Thermo Fisher Scientific Employment.
A. Cartier,
Thermo Fisher Scientific Employment.
A. Rukavishnikov,
Thermo Fisher Scientific Employment.